Scinai Immunotherapeutics (SCNI) Gross Profit (2024 - 2026)

Scinai Immunotherapeutics (SCNI) has 3 years of Gross Profit data on file, last reported at -$1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit fell 590.35% year-over-year to -$1.1 million; the trailing twelve-month figure through Mar 2026 stood at -$2.6 million (changed N/A YoY), and the FY2025 full-year result was -$4.3 million, down 647.24% from the prior year.
• Gross Profit improved to -$1.1 million in Q1 2026, from -$1.5 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $228000.0 in Q1 2025 to a low of -$1.5 million in Q2 2025.
• A 3-year average of -$560800.0 and a median of -$249000.0 in 2024 frame the typical range for Gross Profit.
• Peak annual rise in Gross Profit reached 590.35% in 2026, while the deepest fall reached 590.35% in 2026.
• Tracing SCNI's Gross Profit over 3 years: stood at -$167000.0 in 2024, then sank by 797.01% to -$1.5 million in 2025, then advanced by 25.37% to -$1.1 million in 2026.
• Business Quant data shows SCNI's Gross Profit at -$1.1 million in Q1 2026, -$1.5 million in Q2 2025, and $228000.0 in Q1 2025.